<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1320f–2" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1320f–2/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1320f–2/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1320f_2"><akn:num>1320f–2</akn:num><akn:heading>Manufacturer agreements</akn:heading><akn:content><akn:p>§ 1320f–2. Manufacturer agreements(a) In generalFor purposes of section 1320f(a)(2) of this title, the Secretary shall enter into agreements with manufacturers of selected drugs with respect to a price applicability period, by not later than February 28 following the selected drug publication date with respect to such selected drug, under which—(1) during the negotiation period for the initial price applicability year for the selected drug, the Secretary and the manufacturer, in accordance with section 1320f–3 of this title, negotiate to determine (and, by not later than the last date of such period, agree to) a maximum fair price for such selected drug of the manufacturer in order for the manufacturer to provide access to such price—(A) to maximum fair price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1320f(c)(2) of this title and are dispensed such drug (and to pharmacies, mail order services, and other dispensers, with respect to such maximum fair price eligible individuals who are dispensed such drugs) during, subject to paragraph (2), the price applicability period; and

(B) to hospitals, physicians, and other providers of services and suppliers with respect to maximum fair price eligible individuals who with respect to such drug are described in subparagraph (B) of such section and are furnished or administered such drug during, subject to paragraph (2), the price applicability period;


(2) the Secretary and the manufacturer shall, in accordance with section 1320f–3 of this title, renegotiate (and, by not later than the last date of the period of renegotiation, agree to) the maximum fair price for such drug, in order for the manufacturer to provide access to such maximum fair price (as so renegotiated)—(A) to maximum fair price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1320f(c)(2) of this title and are dispensed such drug (and to pharmacies, mail order se</akn:p></akn:content><akn:subsection eId="subsec_1320f_2_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general For purposes of section 1320f(a)(2) of this title, the Secretary shall enter into agreements with manufacturers of selected drugs with respect to a price applicability period, by not later than February 28 following the selected drug publication date with respect to such selected drug, under which—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_2_b"><akn:num>(b)</akn:num><akn:heading>Agreement in effect until drug is no longer a selected drug</akn:heading><akn:content><akn:p>(b) Agreement in effect until drug is no longer a selected drug An agreement entered into under this section shall be effective, with respect to a selected drug, until such drug is no longer considered a selected drug under section 1320f–1(c) of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_2_c"><akn:num>(c)</akn:num><akn:heading>Confidentiality of information</akn:heading><akn:content><akn:p>(c) Confidentiality of information Information submitted to the Secretary under this part by a manufacturer of a selected drug that is proprietary information of such manufacturer (as determined by the Secretary) shall be used only by the Secretary or disclosed to and used by the Comptroller General of the United States for purposes of carrying out this part.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1320f_2_d"><akn:num>(d)</akn:num><akn:heading>Nonduplication with 340B ceiling price</akn:heading><akn:content><akn:p>(d) Nonduplication with 340B ceiling price Under an agreement entered into under this section, the manufacturer of a selected drug—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>